Skip to main content
OpenTrials
Completed

NCT Number: NCT07073690

Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China

The purpose of this study is to evaluate the treatment patterns and clinical outcomes in adults with lower-risk MDS (LR-MDS) who were erythropoiesis-stimulating agents (ESA)-naïve and received luspatercept treatment in China

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Myelodysplastic Syndromes Bone Marrow Diseases Hematologic Diseases Hemic and Lymphatic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Zhijian Xiao

Tianjin, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants ≥ 18 years of age.
  • Documented diagnosis of no del(5q) MDS that meets lower-risk Myelodysplastic Syndromes (MDS) classification. (Diagnosis criteria and risk classification criteria are based on clinical practice)
  • Patients who were erythropoiesis-stimulating agent (ESA)-naïve have received luspatercept monotherapy at least 2 cycles regardless of RS status.
  • Historical documentation of anemia before luspatercept treatment.

Exclusion criteria

  • Had a history of acute myeloid leukemia (AML) prior to MDS diagnosis.
  • Received stem cell transplant prior to luspatercept treatment initiation.

Treatment and study plan

Luspatercept

Drug

According to the product label

Primary outcomes

  1. Participant red blood cell transfusion independence

    Time frame: Up to 12-weeks

  2. Participants mean hemoglobin (Hb) increase ≥1.5 g/dL

    Time frame: Up to 12-weeks

Secondary outcomes

  1. Participant transfusion independence and increase in hemoglobin (Hb)

    Time frame: Up to 48 weeks

  2. Duration of luspatercept monotherapy treatment

    Time frame: Up to 48 weeks

  3. Health Care Resource Utilization (HCRU)

    Time frame: Up to 48 weeks

Sponsors and collaborators

Lead sponsor

Bristol-Myers Squibb

Industry

Registry information

Official study title

Real-World Treatment Patterns and Outcomes of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes (LR-MDS) in China ('REACH' Study)

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jul 18, 2025
Registry last updated
May 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.